Registrational Miv-cel Data for Stiff Person Syndrome Published in JAMA Neurology, Showing Durable Clinical Benefit

Kyverna Therapeutics has announced the publication of registrational data for miv-cel (CAR-T cell therapy) in patients with Stiff Person Syndrome (SPS) in JAMA Neurology. The findings from the KYSA-8 trial demonstrate unprecedented clinical outcomes, including patients regaining mobility after a single dose, and suggest miv-cel's potential to be the first approved therapy for SPS and the first CAR T-cell therapy for an autoimmune disease.